Press Releases

BAAR, Switzerland, December 3, 2025 – Taiho Oncology Europe GmbH announced today the UK launch of Lytgobi®  (futibatinib), an irreversibly binding fibroblast growth factor receptor (FGFR) inhibitor.^1,3 This development follows the conditional marketing authorisation (4 September 2024) and subsequent National Institute for Health and Care Excellence (NICE) recommendation (11 September 2024) for futibatinib monotherapy as an option for the treatment of eligible adult patients with locally advanced or metastatic cholangiocarcinoma (CCA) with a FGFR2 fusion or rearrangement that have progressed after at least one prior line of systemic therapy.^1,4

BAAR, Switzerland, November 3, 2025 – Taiho Oncology Europe GmbH announced today the availability of Lytgobi® (futibatinib), a novel irreversibly binding fibroblast growth factor receptor (FGFR) inhibitor,¹ in Switzerland. This milestone follows the temporary authorisation by Swissmedic for futibatinib monotherapy for the treatment of adult patients with locally advanced or metastatic bile duct cancer (cholangiocarcinoma) combined with a fusion or rearrangement of FGFR2 when the disease has spread after at least one prior line of systemic therapy.²

BAAR, Switzerland, February, 12, 2025 – Taiho Oncology Europe GmbH announced today the availability of Lytgobi® (futibatinib), a novel irreversibly binding fibroblast growth factor receptor (FGFR) inhibitor,1 in Italy. This milestone follows the conditional marketing authorisation in the European Union for futibatinib monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma (CCA) with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.2

For Trade and Medical Media Only

Availability of Lytgobi (futibatinib) marks the first medicine launched by
Taiho Oncology Europe

BAAR, Switzerland, 1 August 2024 – Taiho Oncology Europe GmbH announced today the introduction of Lytgobi® (futibatinib), a novel irreversibly binding fibroblast growth factor receptor (FGFR) inhibitor,¹ in France. This milestone follows the conditional marketing authorisation in the European Union for futibatinib monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma (CCA) with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.² The Haute Autorité de Santé (HAS) has approved funding for Lytgobi more specifically for patients presenting with intrahepatic CCA and non-eligible to receive FOLFOX chemotherapy.³

For Trade and Medical Media Only

Availability of Lytgobi (futibatinib) marks the first medicine launched by
Taiho Oncology Europe

BAAR, Switzerland, 1 August 2024 – Taiho Oncology Europe GmbH announced today the introduction of Lytgobi® (futibatinib), a novel irreversibly binding fibroblast growth factor receptor (FGFR) inhibitor,¹ in Spain. This milestone follows the conditional marketing authorisation in the European Union for futibatinib monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma (CCA) with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.²

For Trade and Medical Media Only

Availability of Lytgobi (futibatinib) marks the first medicine launched by

Taiho Oncology Europe

BAAR, Switzerland, 11 June 2024 – Taiho Oncology Europe GmbH announced today the introduction of Lytgobi^® (futibatinib), a novel irreversibly binding fibroblast growth factor receptor (FGFR) inhibitor,¹ in Germany. This milestone follows the conditional marketing authorisation in the European Union for futibatinib monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma (CCA) with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.²

LYTGOBI is the first irreversibly binding FGFR inhibitor in the European Union for use in the treatment of patients with cholangiocarcinoma

ZUG, Switzerland, 4 July 2023 - Taiho Oncology Europe GmbH and Taiho Pharmaceutical Co., Ltd., announced today that the European Commission has granted conditional marketing authorization for LYTGOBI® (futibatinib) monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma (CCA) with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

ZUG, Switzerland,27 April 2023– Taiho Oncology Europe GmbH and Taiho Pharmaceutical Co., Ltd. announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the conditional marketing authorization (CMA) of futibatinib for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma (CCA) with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.